Literature DB >> 12124802

Critical tumor-suppressor gene regions on chromosome 3P in major human epithelial malignancies: allelotyping and quantitative real-time PCR.

Eleonora Braga1, Vera Senchenko, Igor Bazov, Witaly Loginov, Jian Liu, Valeria Ermilova, Tatiana Kazubskaya, Raisa Garkavtseva, Natalia Mazurenko, Fedor Kisseljov, Michael I Lerman, George Klein, Lev Kisselev, Eugene R Zabarovsky.   

Abstract

To ascertain the involvement of human chromosome 3p and its established critical TSG regions in various epithelial malignancies, 21 polymorphic and 2 nonpolymorphic 3p markers were allelotyped in nonpapillary RCC, NSCLC, CC and BC from a total of 184 patients. LOH was observed with high frequency in all types of cancer studied: RCC (52/57, 91%), BC (41/51, 80%), NSCLC (30/40, 75%) and CC (27/36, 75%). Interstitial deletions, believed to signal TSG inactivation, were verified using the "L-allele rule" and real-time quantitative PCR. Significant correlation was observed between DNA copy numbers for 2 nonpolymorphic STS markers and LOH data for adjacent polymorphic loci. Interstitial deletions in 3p were demonstrated for all cancer types studied. However, the distribution of different types of deletion was characteristic for tumors from various locations. Large terminal deletions were predominantly seen in RCC and NSCLC (51% and 40%, respectively), correlating with clear cell RCC and squamous cell carcinomas of the lung. In addition to the LUCA region at 3p21.3 (centromeric), we found that the AP20 region (3p21.3, telomeric) was frequently affected in all 4 cancers, suggesting that this newly defined critical region contains multiple TSGs. Moreover, at least 3 candidate cancer-specific loci were identified. The telomeric 3p26.1-p25.3 region was predominantly deleted in RCC and NSCLC. The D3S1286 and D3S3047 markers (3p25.2-p24.3) were deleted nonrandomly in NSCLC. High-frequency LOH was detected in a segment mapped closely distal to the LUCA site (3p21.3), around the D3S2409 and D3S2456 markers. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 12124802     DOI: 10.1002/ijc.10511

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  14 in total

1.  Identification of 5 novel genes methylated in breast and other epithelial cancers.

Authors:  Victoria K Hill; Luke B Hesson; Temuujin Dansranjavin; Ashraf Dallol; Ivan Bieche; Sophie Vacher; Stella Tommasi; Timothy Dobbins; Dean Gentle; David Euhus; Cheryl Lewis; Reinhard Dammann; Robyn L Ward; John Minna; Eammon R Maher; Gerd P Pfeifer; Farida Latif
Journal:  Mol Cancer       Date:  2010-03-05       Impact factor: 27.401

2.  A screen for conditional growth suppressor genes identifies the Drosophila homolog of HD-PTP as a regulator of the oncoprotein Yorkie.

Authors:  M Melissa Gilbert; Marla Tipping; Alexey Veraksa; Kenneth H Moberg
Journal:  Dev Cell       Date:  2011-05-17       Impact factor: 12.270

3.  Microarray analysis of pediatric ependymoma identifies a cluster of 112 candidate genes including four transcripts at 22q12.1-q13.3.

Authors:  Blanca Suarez-Merino; Mike Hubank; Tamas Revesz; William Harkness; Richard Hayward; Dominic Thompson; John L Darling; David G T Thomas; Tracy J Warr
Journal:  Neuro Oncol       Date:  2005-01       Impact factor: 12.300

4.  Microsatellite analysis of pleural supernatants could increase sensitivity of pleural fluid cytology.

Authors:  Matthias Woenckhaus; Ulrike Grepmeier; Bernhard Werner; Christian Schulz; Felix Rockmann; Peter J Wild; Georg Röckelein; Hagen Blaszyk; Marion Schuierer; Ferdinand Hofstaedter; Arndt Hartmann; Wolfgang Dietmaier
Journal:  J Mol Diagn       Date:  2005-10       Impact factor: 5.568

5.  Simultaneous down-regulation of tumor suppressor genes RBSP3/CTDSPL, NPRL2/G21 and RASSF1A in primary non-small cell lung cancer.

Authors:  Vera N Senchenko; Ekaterina A Anedchenko; Tatiana T Kondratieva; George S Krasnov; Alexei A Dmitriev; Veronika I Zabarovska; Tatiana V Pavlova; Vladimir I Kashuba; Michael I Lerman; Eugene R Zabarovsky
Journal:  BMC Cancer       Date:  2010-03-01       Impact factor: 4.430

6.  A Comprehensive Study of Progressive Cytogenetic Alterations in Clear Cell Renal Cell Carcinoma and a New Model for ccRCC Tumorigenesis and Progression.

Authors:  Zhongfa Zhang; Bill Wondergem; Karl Dykema
Journal:  Adv Bioinformatics       Date:  2010-07-05

7.  MicroRNA expression differentiates histology and predicts survival of lung cancer.

Authors:  Maria Teresa Landi; Yingdong Zhao; Melissa Rotunno; Jill Koshiol; Hui Liu; Andrew W Bergen; Maurizia Rubagotti; Alisa M Goldstein; Ilona Linnoila; Francesco M Marincola; Margaret A Tucker; Pier Alberto Bertazzi; Angela C Pesatori; Neil E Caporaso; Lisa M McShane; Ena Wang
Journal:  Clin Cancer Res       Date:  2010-01-12       Impact factor: 12.531

Review 8.  A Decade of GWAS Results in Lung Cancer.

Authors:  Yohan Bossé; Christopher I Amos
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-06-14       Impact factor: 4.254

9.  High mutability of the tumor suppressor genes RASSF1 and RBSP3 (CTDSPL) in cancer.

Authors:  Vladimir I Kashuba; Tatiana V Pavlova; Elvira V Grigorieva; Alexey Kutsenko; Surya Pavan Yenamandra; Jingfeng Li; Fuli Wang; Alexei I Protopopov; Veronika I Zabarovska; Vera Senchenko; Klas Haraldson; Tatiana Eshchenko; Julia Kobliakova; Olga Vorontsova; Igor Kuzmin; Eleonora Braga; Vladimir M Blinov; Lev L Kisselev; Yi-Xin Zeng; Ingemar Ernberg; Michael I Lerman; George Klein; Eugene R Zabarovsky
Journal:  PLoS One       Date:  2009-05-29       Impact factor: 3.240

10.  Similar expression to FGF (Sef) inhibits fibroblast growth factor-induced tumourigenic behaviour in prostate cancer cells and is downregulated in aggressive clinical disease.

Authors:  S Darby; T Murphy; H Thomas; C N Robson; H Y Leung; M E Mathers; V J Gnanapragasam
Journal:  Br J Cancer       Date:  2009-11-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.